Clinical trials: Malignancies Multiple
Cystic Fibrosis, Pulmonary Fibrosis
Role of Genetic Factors in the Development of Lung Disease
This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease.
- Conditions
- Cystic Fibrosis, Pulmonary Fibrosis, Tuberous Sclerosis, Asthma
- Trial name
- NCT00001532
- Where
- 2 sites in United States
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Colorectal Cancer, Chemotherapy
Supportive Cancer Care Networkers (SCAN)
Aim of the study is to increase the proportion of indicated patients with colorectal cancer undergoing adjuvant chemotherapy following surgical resection through an optimized symptom management and logistical support.
- Trial name
- SCAN (NCT01651832)
- Testing
- SCAN
- Where
- 9 sites in Germany
- Volunteers
- 261 people
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg
Prostatic Neoplasm
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
The purpose of this study is to evaluate the efficacy and safety of AAA617 alone (Lutetium [177Lu] vipivotide tetraxetan) and in combination with an Androgen Receptor Pathway Inhibitors (ARPI) in participants with PSMA-positive…
- Trial name
- PSMACare (NCT05849298)
- Testing
- AAA617, AAA517, Piflufolastat F 18
- Where
- 31 sites in United States, Brazil and 9 more
- Volunteers
- 49 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Hormone Receptor Positive Tumor
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
The purpose of this study is to evaluate the efficacy and quality of life in women with advanced breast cancer (locally advance inoperable or metastatic adenocarcinoma of the breast), HR+ / HER2-, who are treated with an…
- Conditions
- Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Trial name
- INGE-B (NCT02894398)
- Testing
- Palbociclib, Letrozole, Anastrozole
- Where
- 70 sites in Germany
- Volunteers
- 388 people
- Sponsor
- iOMEDICO AG
Carcinoma, Renal Cell
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)
This is a Phase 3, open-label, randomized, controlled, multi-national, multi-center, parallel-arm study comparing tivozanib to sorafenib in participants with refractory advanced renal cell carcinoma (RCC).
- Trial name
- NCT02627963
- Testing
- Tivozanib hydrochloride, Sorafenib
- Where
- 191 sites in United States, Belgium and 10 more
- Volunteers
- 350 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Colon Cancer (Stage II &Amp; III), Immunotherapy
Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study
The goal of this prospective, single-center, multi-cohort clinical trial is to evaluate the efficacy and safety of neoadjuvant Iparomlimab/Tuvonralimab combined with CAPEOX, with or without propranolol, in patients with locally…
- Conditions
- Colon Cancer (Stage II &Amp; III), Immunotherapy, Beta Blocker, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT07549906
- Testing
- Iparomlimab/Tuvonralimab, Capecitabine, Oxaliplatin
- Volunteers
- 45 people
- Sponsor
- Sun Yat-sen University
Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
Phase III Study to Investigate the Efficacy and Safety of CS1001 or Placebo in Combination with FP as First-Line Therapy in Subjects with Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04187352
- Testing
- CS1001+ Fluorouracil+Cisplatin
- Where
- 72 sites in China
- Volunteers
- 540 people
- Sponsor
- CStone Pharmaceuticals
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have…
- Trial name
- NCT00031915
- Testing
- imatinib mesylate
- Where
- 10 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Cancer, Pain
Pilot Study to Evaluate the Safety and Analgesic Activity of M40403 Co-Administered With an Opioid Agent for Cancer Pain
M40403 was found to be effective in reducing pain in animal models and in clinical studies of subjects who were experiencing pain after dental surgery.
- Trial name
- NCT00101621
- Testing
- M40403
- Volunteers
- 24 people
- Sponsor
- MetaPhore Pharmaceuticals
HIV Infections
Workplace-based HIV Self-testing Among Men in Uganda (WISe-Men)
This study seeks to determine whether workplace delivery of HIV self-testing will lead to an increase in uptake of HIV testing and subsequent linkage to care or prevention services among men in Uganda.
- Trial name
- NCT04164433
- Testing
- Oral HIV Self-Test (OraQuick)
- Where
- 2 sites in Uganda
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- Makerere University
Multiple Myeloma, Lymphoma, Non-Hodgkin's
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with…
- Trial name
- NCT04756726
- Testing
- cemsidomide, Dexamethasone Oral
- Where
- 13 sites in United States
- Volunteers
- 224 people
- Sponsor
- C4 Therapeutics, Inc.
Multiple Myeloma
CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma
Multiple myeloma (MM) is an incurable plasma cell cancer that almost all patients eventually relapse despite advancement in treatment strategies.
- Trial name
- NCT04727008
- Testing
- CXCR4 modified anti-BCMA CAR T cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Sichuan University
Biliary Tract Tumors
QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors
QL1706 Combined with Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors：A Single - Arm, Open - Label, Multi - Center, Prospective Phase II Clinical Trial (Spring Study)
- Trial name
- Spring (NCT06892925)
- Testing
- QL1706
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hedgehog Pathway, Smoothened
A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer
The purpose of this study is to determine the safety of BMS-833923 (XL139) in patients with advanced or metastatic cancers and determine the recommended phase 2 dose range and schedule
- Conditions
- Hedgehog Pathway, Smoothened, Basal Cell Carcinoma (BCC), Basal Cell Nevoid Syndrome (BCNS)
- Trial name
- NCT00670189
- Testing
- BMS-833923 (XL139)
- Where
- 3 sites in United States, Canada
- Volunteers
- 53 people
- Sponsor
- Bristol-Myers Squibb
Deafness, Kidney Diseases
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors
The von Hippel Lindau (VHL) gene has recently been identified as the genetic defect resulting in a syndrome of multiple neoplasias.
- Conditions
- Deafness, Kidney Diseases, Kidney Neoplasms, Neoplasms
- Trial name
- NCT00001668
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Neoplasms, Cancer
PRediction Of Five Usual Tumors Using Blood Test for Risk Assessment and Early Detection
Liquid biopsy technology based on cell-free nucleic acids and protein characteristics has unique advantages and significant application prospects in cancer early detection.
- Trial name
- PROFUTURE (NCT05874648)
- Testing
- Multi-cancer early detection test
- Where
- China
- Volunteers
- 3,830 people, healthy volunteers welcome
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Multiple Myeloma, Hypogammaglobulinemia
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).
- Conditions
- Multiple Myeloma, Hypogammaglobulinemia, Hypogammaglobulinemia, Acquired
- Trial name
- NCT06976476
- Testing
- IgPro20
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Carcinoma, Non-Small-Cell Lung
Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung Cancer
The purpose of this study is to examine the efficacy of Bevacizumab in addition to platinum-based chemotherapy for first-line treatment of participants with advanced stage (IIIB/IV) non-small cell lung cancer (NSCLC) other than…
- Trial name
- AVALANCHE (NCT03170284)
- Testing
- Bevacizumab
- Where
- 33 sites in Hungary
- Volunteers
- 150 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
The objective of this study is to assess the efficacy, safety of MRG003 as single agent in EGFR-positive advanced non-small cell lung cancer
- Trial name
- NCT04838548
- Testing
- MRG003
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Lepu Biopharma Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.